Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Colorectal Neoplasms 36Breast Neoplasms 29Pancreatic Neoplasms 20Rectal Neoplasms 17Stomach Neoplasms 16Neoplasm Metastasis 16Neoplasms 12Esophageal Neoplasms 8Triple Negative Breast Neoplasms 7Colonic Neoplasms 7Colorectal Cancer Metastatic 6Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Brain Neoplasms 4Adenocarcinoma 4Head and Neck Neoplasms 3Gastrointestinal Neoplasms 3Biliary Tract Neoplasms 3Bile Duct Neoplasms 3Advanced Solid Tumors 3Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Liver Neoplasms 2Diabetes Mellitus, Insulin-Dependent, 12 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2

Interventions

pembrolizumab 9avelumab 8Nivolumab 6Ipilimumab 4Radiotherapy 3durvalumab 2cemiplimab 2atezolizumab 2aldesleukin 2Specimen Handling 2Radiation 2Magnetic Resonance Spectroscopy 2Interferon-beta 2Cyclophosphamide 2Biopsy 2Bevacizumab 2tremelimumab 1sargramostim 1sapanisertib 1regorafenib 1prednylidene 1poly ICLC 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1lutetium Lu 177 dotatate 1interferon gamma-1b 1epacadostat 1efineptakin alfa 1deltacortene 1decitabine and cedazuridine drug combination 1bempegaldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Merkel Cell × Capecitabine × Clear all
NCT03167164 2025-02-21

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡